Literature DB >> 30745385

Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Xingchen Bian1,2, Xiaofen Liu1, Yuancheng Chen1,3, Daijie Chen4, Jian Li5, Jing Zhang6,3.   

Abstract

Colistin-based combination therapy has become an important strategy to combat the carbapenem-resistant Acinetobacter baumannii (CRAB). However, the optimal dosage regimen selection for the combination with maximum efficacy is challenging. Checkerboard assay was employed to evaluate the synergy of colistin in combination with meropenem, rifampin, fosfomycin, and minocycline against nine carbapenem-resistant A. baumannii isolates (MIC of meropenem [MICMEM], ≥32 mg/liter) isolated from Chinese hospital-acquired pneumonia (HAP) patients. A static time-kill assay, in vitro dynamic pharmacokinetic/pharmacodynamic (PK/PD) model, and semimechanistic PK/PD modeling were conducted to predict and validate the synergistic effect of the most efficacious combination. Both checkerboard and static time-kill assays demonstrated the superior synergistic effect of the colistin-meropenem combination against all CRAB isolates. In the in vitro PK/PD model, the dosage regimen of 2 g meropenem daily via 3-h infusion combined with steady-state 1 mg/liter colistin effectively suppressed the bacterial growth at 24 h with a 2-log10 decrease, compared with the initial inocula against two CRAB isolates. The semimechanistic PK/PD model predicted that more than 2 mg/liter colistin combined with meropenem (2 g, 3-h infusion) was required to achieve the killing below the limit of detection (<LOD; i.e., 1 log10CFU/ml) at 24 h with an MICMEM of ≥32 mg/liter. Colistin combined with meropenem exerted synergistic killing against CRAB even with an MICMEM of ≥32 mg/liter and MIC of colistin (MICCST) of ≤1 mg/liter. However, it is predicted that a higher concentration of colistin combined with meropenem was crucial to kill bacteria to <LOD. Our study provides important PK/PD information for optimization of the colistin and meropenem combination against CRAB.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter baumanniizzm321990; PK/PD modeling; carbapenem resistance; colistin; combination therapy; meropenem

Year:  2019        PMID: 30745385      PMCID: PMC6437507          DOI: 10.1128/AAC.01989-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

Review 1.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

2.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

Review 3.  Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs.

Authors:  Elisabet I Nielsen; Lena E Friberg
Journal:  Pharmacol Rev       Date:  2013-06-26       Impact factor: 25.468

4.  Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock.

Authors:  Fabio Silvio Taccone; Frédéric Cotton; Sandrine Roisin; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

5.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

6.  Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment.

Authors:  Rachel L Soon; Roger L Nation; Stewart Cockram; Jennifer H Moffatt; Marina Harper; Ben Adler; John D Boyce; Ian Larson; Jian Li
Journal:  J Antimicrob Chemother       Date:  2010-11-16       Impact factor: 5.790

7.  Biological features of biofilm-forming ability of Acinetobacter baumannii strains derived from 121 elderly patients with hospital-acquired pneumonia.

Authors:  Duchao Zhang; Jingjing Xia; Yaping Xu; Meiliang Gong; Yu Zhou; Lixin Xie; Xiangqun Fang
Journal:  Clin Exp Med       Date:  2014-12-28       Impact factor: 3.984

8.  Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme.

Authors:  Wing Yau; Roxanne J Owen; Anima Poudyal; Jan M Bell; John D Turnidge; Heidi H Yu; Roger L Nation; Jian Li
Journal:  J Infect       Date:  2008-12-06       Impact factor: 6.072

9.  Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

Authors:  Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Thomas A Robertson; Andrew J Dalley; Jeffrey Lipman
Journal:  J Antimicrob Chemother       Date:  2009-04-27       Impact factor: 5.790

Review 10.  Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.

Authors:  Lisa L Maragakis; Trish M Perl
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

View more
  4 in total

1.  Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Jun Mao; Ting Li; Na Zhang; Shuaishuai Wang; Yaowen Li; Yu Peng; Huiping Liu; Guang Yang; Yisong Yan; Lifang Jiang; Yanyan Liu; Jiabin Li; Xiaohui Huang
Journal:  Microbiol Spectr       Date:  2021-12-01

2.  Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model.

Authors:  Xingyi Qu; Xingchen Bian; Yuancheng Chen; Jiali Hu; Xiaolan Huang; Yu Wang; Yaxin Fan; Hailan Wu; Xin Li; Yi Li; Beining Guo; Xiaofen Liu; Jing Zhang
Journal:  Molecules       Date:  2022-02-06       Impact factor: 4.411

Review 3.  Pharmacokinetic/Pharmacodynamic Modeling and Application in Antibacterial and Antifungal Pharmacotherapy: A Narrative Review.

Authors:  Laiz Campos Pereira; Marcelo Aguiar de Fátima; Valdeene Vieira Santos; Carolina Magalhães Brandão; Izabel Almeida Alves; Francine Johansson Azeredo
Journal:  Antibiotics (Basel)       Date:  2022-07-22

Review 4.  Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?

Authors:  Song Oh; Raymond Chau; Anh T Nguyen; Justin R Lenhard
Journal:  Antibiotics (Basel)       Date:  2021-05-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.